Characterization of Casirivimab Plus Imdevimab, Sotrovimab, and Bamlanivimab Plus Etesevimab-Derived Interference in Serum Protein Electrophoresis and Immunofixation ElectrophoresisArticle Published on 2022-10-292022-11-15 Journal: The journal of applied laboratory medicine [Category] [DOI] 10.1093/jalm/jfac064 PMC 바로가기
SARS-CoV-2 neutralizing antibodies for COVID-19: Outcomes for bamlanivimab versus bamlanivimab-etesevimab combination in a racially diverse cohort of patients with significant comorbiditiesArticle Published on 2022-09-012022-11-15 Journal: Journal of clinical pharmacy and therapeutics [Category] [DOI] 10.1111/jcpt.13694 PMC 바로가기
Evolution of Anti-SARS-CoV-2 Therapeutic AntibodiesArticle Published on 2022-08-282022-11-15 Journal: International Journal of Molecular Sciences [Category] [DOI] 10.3390/ijms23179763 PMC 바로가기
A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load코로나19 고위험 보행 환자를 대상으로 한 밤라니비맙과 에테세비맙의 무작위 위약 대조 임상 시험 및 지속적으로 높은 바이러스 부하의 예후 가치 검증Randomized Controlled Trial Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] [DOI] 10.1093/cid/ciab912 PMC 바로가기 [Article Type] Randomized Controlled Trial
Immune Escape Mechanisms of SARS-CoV-2 Delta and Omicron Variants against Two Monoclonal Antibodies That Received Emergency Use Authorization긴급 사용 승인을 받은 2개의 단클론 항체에 대한 SARS-CoV-2 Delta 및 Omicron 변이체의 면역 탈출 메커니즘Article Published on 2022-07-072022-09-11 Journal: The journal of physical chemistry letters [Category] [DOI] 10.1021/acs.jpclett.2c00912 PMC 바로가기 [Article Type] Article
Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infectionSARS-CoV-2 감염에 대한 외래 환자 환경에서 투여된 밤라니비맙 및 에테세비맙Article Published on 2022-07-012022-09-12 Journal: Pathogens and global health [Category] [DOI] 10.1080/20477724.2021.2024030 PMC 바로가기 [Article Type] Article
Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study질병 진행 위험이 높은 경증에서 중등도 COVID-19 환자를 대상으로 한 다양한 단일 클론 항체 요법의 임상 효능: 전향적 코호트 연구Observational Study Published on 2022-07-012022-09-11 Journal: European Journal of Clinical Microbiology & Infect [Category] [DOI] 10.1007/s10096-022-04464-x PMC 바로가기 [Article Type] Observational Study
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2SARS-CoV-2 오미크론 하위 계통 BA.1 및 BA.2에 대한 허가된 단일 클론 항체 및 항바이러스제의 효능Article Published on 2022-06-232022-09-11 Journal: Viruses [Category] [DOI] 10.3390/v14071374 PMC 바로가기 [Article Type] Article
PK/PD modeling links accelerated resolution of COVID-19-related clinical symptoms to SARS-CoV-2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab togetherPK/PD 모델링은 밤라니비맙 단독 또는 밤라니비맙과 에테세비맙을 함께 치료한 후 환자의 SARS-CoV-2 바이러스 부하 감소와 COVID-19 관련 임상 증상의 가속화된 해결을 연결합니다.Clinical Trial Published on 2022-06-012022-09-12 Journal: CPT: pharmacometrics & systems pharmacology [Category] [DOI] 10.1002/psp4.12784 PMC 바로가기 [Article Type] Clinical Trial
Therapeutic monoclonal antibodies for COVID-19 management: an updateReview Published on 2022-06-012023-07-09 Journal: Expert opinion on biological therapy [Category] [DOI] 10.1080/14712598.2022.2078160 PMC 바로가기 [Article Type] Review